Fingerprint
Dive into the research topics of 'Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically